Validation of \textit{COL11A1}/procollagen 11A1 expression in TGF-\(\beta\)1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma

José A Galván\textsuperscript{1,2,6}, Jorge García-Martínez\textsuperscript{1,2}, Fernando Vázquez-Villa\textsuperscript{2}, Marcos García-Ocaña\textsuperscript{2,3}, Carmen García-Pravia\textsuperscript{2,4}, Primitiva Menéndez-Rodríguez\textsuperscript{4}, Carmen González-del Rey\textsuperscript{4}, Luis Barneo-Serra\textsuperscript{1,2} and Juan R de los Toyos\textsuperscript{2,5,*}

Abstract

\textbf{Background:} The human \textit{COL11A1} gene has been shown to be up-regulated in stromal cells of colorectal tumours, but, so far, the immunodetection of procollagen 11A1, the primary protein product of \textit{COL11A1}, has not been studied in detail in human colon adenocarcinomas. Some cancer-associated stromal cells seem to be derived from bone marrow mesenchymal cells; the expression of the \textit{COL11A1} gene and the parallel immunodetection of procollagen 11A1 have not been evaluated in these latter cells, either.

\textbf{Methods:} We used quantitative RT-PCR and/or immunocytochemistry to study the expression of \textit{DES}/desmin, \textit{VIM}/vimentin, \textit{ACTA2}/\(\alpha\)SMA (alpha smooth muscle actin) and \textit{COL11A1}/procollagen 11A1 in HCT 116 human colorectal adenocarcinoma cells, in immortalised human bone marrow mesenchymal cells and in human colon adenocarcinoma-derived cultured stromal cells. The immunodetection of procollagen 11A1 was performed with the new recently described DMTX1/1E8.33 mouse monoclonal antibody. Human colon adenocarcinomas and non-malignant colon tissues were evaluated by immunohistochemistry as well. Statistical associations were sought between anti-procollagen 11A1 immunoscoring and patient clinicopathological features.

\textbf{Results:} Procollagen 11A1 was immunodetected in human bone marrow mesenchymal cells and in human colon adenocarcinoma-associated spindle-shaped stromal cells but not in colon epithelial or stromal cells of the normal colon. This immunodetection paralleled, in both kinds of cells, that of the other mesenchymal-related biomarkers studied: vimentin and \(\alpha\) smooth muscle actin, but not desmin. Thus, procollagen 11A1\textsuperscript{+} adenocarcinoma-associated stromal cells are similar to "activated myofibroblasts". In the series of human colon adenocarcinomas here studied, a high procollagen 11A1 expression was associated with nodal involvement \((p = 0.05)\), the development of distant metastases \((p = 0.017)\), and advanced Dukes stages \((p = 0.047)\).

\textbf{Conclusion:} The immunodetection of procollagen 11A1 in cancer-associated stromal cells could be a useful biomarker for human colon adenocarcinoma characterisation.

\textbf{Keywords:} Procollagen 11A1, Human bone marrow mesenchymal cells, Cancer-associated stromal cells, Human colon adenocarcinoma

* Correspondence: jrttoyos@uniovi.es
\textsuperscript{1}Oncology University Institute of the Principality of Asturias (IUOPA), 33006 Oviedo, Spain
\textsuperscript{2}Immunology Department, School of Medicine and Health Sciences, University of Oviedo, c/ Julián Clavería s/n, 33006 Oviedo, Spain

Full list of author information is available at the end of the article.

© 2014 Galván et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
A wealth of studies have reported that the COL11A1 human gene, coding for the α1 chain of procollagen and mature collagen of type XI, which is an extracellular minor fibrillar collagen, is up-regulated in some human tumours and in mesenchymal-derived tumour cell lines [1-32], as well as in mesenchymal stem cells and osteoblasts [33-35].

Collagen polypeptides are synthesized as procollagens, with the N- and C-propeptides at the ends of the prototypical collagen triple helix. Upon secretion, the propeptides are excised and then the mature collagen molecules assemble in fibrils.

In tumours, the expression of the COL11A1 gene is currently associated to a fibroblast-like stromal phenotype [12,19] but the origin and nature of the cells which produce procollagen and collagen 11A1 remain controversial to some extent [26].

The so-called cancer-associated stromal cells, resulting from the desmoplastic reaction which accompanies the development of human invasive carcinomas, comprise cells of different types, and are at least in part derived from mesenchymal progenitors and local resident cells. It is also well-established that TGF-β1 in cancer promotes the activation of cancer-associated stromal cells [36].

For the present study, we set out to verify the expression of the COL11A1 gene, by quantitative RT-PCR in TGF-β1-exposed epithelial human colorectal HCT 116 cells and Immortalised Human Bone Marrow Mesenchymal Cells (hTERT-HMCs); and the expression of procollagen 11A1 by immunocytochemistry (ICC)/immunohistochemistry (IHC), using the DMTX1/1E8.33 monoclonal antibody (mAb) [37], on those cell cultures as well as on biopsies of human colon adenocarcinomas. Concurrently, we studied the expression of DES/desmin, VIM/vimentin and ACTA2/αSMA (alpha smooth muscle actin) as mesenchymal (myofibroblast)/stromal markers.

Within the N-propeptide of human procollagen 11A1, it is the so-called “variable region”, the most divergent amino acid sequence stretch among different procollagens. The DMTX1/1E8.33 mAb recognises an epitope in the YNYGTMESYQTEAPR amino acid stretch within the variable region of human procollagen 11A1 [37].

Methods
Cell cultures
Ascorbate is a well-known inducer of the synthesis of some collagens [38,39]; thus, to favour the expression of procollagen 11A1, cells were habitually cultured with this supplement. Since TGF-β1 levels are increased in the serum of patients with invasive carcinomas [40], we chose to analyse its effects after continued and protracted exposure of cell cultures to this cytokine.

The human colorectal adenocarcinoma HCT 116 (CCL-247) cell line, derived from a primary tumour, was obtained from the American Type Culture Collection (ATCC) and cultured in DMEM, supplemented with 1 mM sodium pyruvate (Biochrom), 2 mM L-glutamine (Biochrom), 1X non-essential amino acids (Biochrom), 10% foetal bovine serum (Biochrom), and ascorbate 2-phosphate (37.5 μg/ml) (Wako Chemicals).

Immortalised Human Bone Marrow Mesenchymal Cells-hTERT (hTERT-HMCs) were obtained from Applied Biological Materials (ABM) Inc., Richmond, BC, Canada (Cat. No. T0523), and grown in T25 ECM-coated flasks in Prigrow II medium (ABM, Cat. No. TM002), with the addition of 10% foetal bovine serum, 1 μM hydrocortisone (Sigma) and ascorbate 2-phosphate (37.5 μg/ml) (Wako Chemicals).

For TGF-β1 induction, media were further supplemented with 10 ng/ml of recombinant TGF-β1 (Peprotech). The medium was replaced every 3–4 days and the cells were cultured for at least 15 days.

All the cultures were carried out in a humidified atmosphere of 5% CO₂ in air at 37°C.

Culture passages and cell collections were done with trypsin/EDTA 0.05%/0.02% (Biochrom). Three different harvests from each cell culture type were obtained; for Q-RT-PCR, fresh cell pellets were kept at −80°C.

Colon adenocarcinoma stromal cells isolation and culture
Fresh human tissue samples were procured after written informed consent of the patients and approval by the Principality of Asturias Ethics Committee of Clinical Research, Oviedo, Spain.

Short-term cultures of colon adenocarcinoma stromal cells were carried out, as previously described [41], from samples of tumoral sites, avoiding necrotic areas. A sample from the operating theatre was directly transferred to a sterile tube containing DMEM culture medium (Gibco, Invitrogen), supplemented with vancomycin (40 μg/ml) and amikacin (40 μg/ml) (Normon Laboratories, Madrid, Spain), and stored for 24 hours at 4°C.

After three washings with phosphate buffer saline (PBS), the sample was cut into several small fragments. These fragments were first incubated with collagenases (Type I 2 mg/ml, Sigma) for 1.5 hours and then centrifuged to eliminate supernatant; subsequently, the pellet was subjected to a second incubation in trypsin/EDTA for 30 min. After digestion, the cells were again collected in a pellet, resuspended in DMEM culture medium, supplemented with 10% foetal bovine serum, L-glutamine and penicillin/streptomycin, transferred to T-flasks and cultivated in 5% CO₂ at 37°C.

Stromal cell cultures were stable up to 5–6 passages before going into senescence. The purity of these stromal
cell cultures was assessed by morphology and by immunostaining for vimentin.

**Q-RT-PCR**

For normalisation of data, quantitative RT-PCR of DES, VIM, ACTA2 and COL11A1 mRNA, and PUM1, RPL10, and GAPDH mRNA was performed using the BioMark™ HD System of the Fluidigm technology (Fluidigm, San Francisco, USA).

Briefly, total RNA was isolated from pooled cell cultures, kept at ~80°C, with the RNeasy Mini kit (Qiagen). cDNA was synthesized from 100 ng of RNA from each sample, using the AffinityScript Multiple Temperature cDNA Synthesis kit (Agilent Technologies). A pre-amplification was carried out, applying the QIAGEN® Multiplex PCR Kit and the pool of all the 20x TaqMan® Gene Expression Assays. Real time Q-PCR reactions were carried out with the TaqMan Universal PCR Master Mix kit (Applied Biosystems). Further details, according to Applied Biosystems’ recommendations, are in Table 1.

Data were normalised by applying the ΔCt method, after PCR efficiency corrections. These analyses were performed by Progenika Biopharma, S.A., Derio, Spain.

Three independent samples (n = 3) of different cell harvests of each cell type were studied. Data are presented as mean and SEM. For each gene, differences between cell culture expressions were analysed by a two-tailed unpaired t-test. A P value <0.01 was considered statistically significant.

**Immunohistochemistry (IHC)**

For immunohistochemical techniques, a cohort of 51 patients with colon adenocarcinoma and 6 patients diagnosed with incipient bowel infarction were collected from the Archive of the Pathology Department, Asturias Central University Hospital, with the Principality of Asturias Ethics Committee of Clinical Research, Oviedo, Spain, approval for guidelines on ethical procedures. The specimens were assessed by three observers (JAG, CGP, and CGR), following these criteria: procollagen 11A1 immunostaining was evaluated according to the cytoplasmatic signal as the product of two parameters: extent of immunoreactivity, which was evaluated in the most densely stained area (hot spot) under the 20× objective and scored on a 0–3 scale, according to the proportion of positive fibroblasts: (0) 0%; (1) <10%; (2) 10-50% and (3) >50%; and granularity in the cytoplasm, evaluated as dispersed vs. confluent (1 and 2 points, respectively), with the 40× objective. Immunoscore values ranged from 0 to 6. Adjacent non-malignant tissue was used as a negative control.

**Statistical analysis**

The experimental results were tested for significance employing the χ² test (with Yates’ correction, when appropriate). The statistical analysis was carried out with
the IBM SPSS 20.0 software package (SPSS, Inc., Chicago, IL). All tests were two-sided and p < 0.05 values were considered statistically significant.

**Results**

**Study of human cell cultures**

So far, we are not aware of any human colorectal cell line in which the expression of the COL11A1 gene has been reported, but we had observed that primary cultures of bone marrow-derived human mesenchymal cells, expressed COL11A1/procollagen 11A1, especially after long exposure (≥15 days) to TGF-β1 (data not shown).

We have presently studied the well-known epithelial human colorectal HCT 116 cell line as a negative control for the expression of the mesenchymal DES, VIM, ACTA2 and COL11A1 genes in relation to their expression by cultured immortalised hTERT-HMCs. The expression of the DES, VIM, ACTA2 and COL11A1 genes was analysed by Q-RT-PCR; the immunodetection of desmin, vimentin, αSMA and procollagen 11A1 was performed by ICC.

According to the normalised Q-RT-PCR data we have obtained (Figure 1), TGF-β1-activated hTERT-HMCs did not express DES mRNA, but noticeable amounts of VIM, ACTA2 and COL11A1 mRNA. The corresponding protein expression was confirmed by ICC (Figure 2). An average of 20% of these cells in cultures exposed to TGF-β1 showed a granular pattern of intracytoplasmic immunostaining of procollagen 11A1. None of these markers was expressed by the HCT 116 cells, but certain levels of DES.

**Examination of human tissues**

Fifty one paraffin-embedded archival samples of human colon adenocarcinomas were examined by IHC with the DMTX1/1E8.33 mAb; all cases presented adjacent nonmalignant tissue as control. Six cases of incipient bowel infarction were similarly studied. Table 3 shows the characteristics of patients and samples, and their anti-procollagen 11A1 immunoscores, evaluated as described in Methods; as shown, these immunoscores ranged from 0 to 6. A more detailed description of these characteristics

---

**Table 2 Antibodies used in IHC/ICC analysis**

| Primary antibodies (species) | Clone     | Commercial reference          | Dilution | Incubation time (min) |
|-----------------------------|-----------|-------------------------------|----------|-----------------------|
| Procollagen 11A1 (mAb)      | 1E8.33    | DMTX1/Oncomatrix, Spain       | 1:400    | 30                    |
| Desmin (mAb)                | D33       | Dako, Denmark                 | R-t-U    | 20                    |
| α-SMA (mAb)                 | 1A4       | Dako, Denmark                 | R-t-U    | 20                    |
| Vimentin (pAb)              | C-20      | Santa Cruz Biotech, Germany   | 1:600    | 10                    |

*mAb*: Mouse monoclonal antibody.  
*pAb*: Rabbit polyclonal antibodies.  
*R-t-U*: Ready-to-Use.

---

**Figure 1** Q-RT-PCR data of DES, VIM, ACTA2 and COL11A1 mRNA expression in cell cultures of the HCT 116 cell line and in immortalised hTERT-HMCs, both after long exposure to ascorbate 2-phosphate and TGF-β1. The data were normalised in relation to PUM1, RPL10, and GAPDH mRNA expression (n =3; mean ± SEM; *P <0.05, **P <0.01).
is in Additional file 1. In three of these 51 diagnosed adenocarcinoma cases, no procollagen 11A1 staining could be detected, in spite of extensive re-examination. Procollagen 11A1 was neither immunodetected in the adjacent non-malignant tissues nor in the infarction cases.

Figure 3 shows representative procollagen 11A1 immunostaining patterns (panels A, B, C and D); only a granular cytoplasmic staining of peritumoral spindle-shaped fibroblast-like stromal cells was observed. This granularity was either dispersed, with a few granules in the cytoplasm of stromal cells (panel G) or frankly confluent (panel H). No staining was observed on specimens of bowel ischemia (panel E) or on non-malignant tissues (panel F).

Figure 4 shows a representative immunostaining of an adenocarcinoma specimen with a procollagen 11A1 immunoscore of 6. As shown on panel A, only peritumoral stromal cells were stained with the anti-procollagen 11A1 mAb; besides, these cells seemed to be positive for αSMA (C) and vimentin (D), but negative for desmin (B). This immunostaining pattern was reproduced (panels E, F, G and H) in stromal cells cultured from fresh specimens of the same patient.

Association between procollagen 11A1 expression and clinicopathological features

For statistical purposes, some variables (age at diagnosis, tumour size, anti-procollagen 11A1 immunostaining) were divided into 2 groups, taking the median score value as a cut-off point (Table 4). Patients diagnosed with ischemia were excluded from this analysis.

9/12 patients that had developed distant metastases at diagnosis and 15/27 patients with advanced Dukes stages were associated with high procollagen 11A1 expression ($p = 0.017$ and $p = 0.047$, respectively). The same can be observed for 15/26 patients with nodes affected, however, only with a trend towards significance ($p = 0.059$).

Discussion

We have presently shown, extending our previous observations [42], that procollagen 11A1, as a protein expression product of the COL11A1 gene, is immunodetected in stromal cells of human colon adenocarcinoma. By contrast, and contrary to a previous report [15], we have never observed immunodetection of procollagen 11A1 in epithelial cells of normal colon tissue or colon adenocarcinoma with the DMTX1/1E8.33 mAb. This immunodetection was observed in 48 of the 51 cases studied. Three cases (5.9%), which were classified under the same criteria as the rest of the cases examined as conventional adenocarcinomas with desmoplastic reaction, did not stain; so far, we have not identified in them any characteristics to which this negative immunostaining could be associated. Except for the report of Fischer et al. [1] who did not find either the expression of COL11A in 5 out of 15 (33.3%) colonic carcinomas analysed, we are not aware...
of any more studies reporting the percentage of colon adenocarcinomas expressing the COL11A1 gene; this aspect should be studied in detail.

We have very recently reported that procollagen 11A1+ cancer-associated stromal cells of pancreatic ductal adenocarcinoma co-express αSMA, and/or vimentin, and/or desmin in different proportions [41]. We have now confirmed, by Q-RT-PCR and IHC/ICC, the stromal expression of human procollagen 11A1 in colon adenocarcinoma. Although not formally proven, procollagen 11A1+ colon adenocarcinoma stromal cells, being spindle-shaped, seem to simultaneously express alpha smooth muscle actin and vimentin, but no desmin; these traits confer to them a myofibroblast-like phenotype rather than a pericyte one [43]. While in the desmoplastic component of hepatocellular carcinomas and pancreatic ductal adenocarcinomas there is a significant contribution of desmin + stellate cells, this is not the case in colon adenocarcinomas. As normal resident intestinal myofibroblasts are not immunoreactive to the DMTX1/1E8.33 mAb, these procollagen 11A1+ desmin− colon adenocarcinoma stromal cells could be a type of "activated myofibroblasts".

We have also shown that a fraction of cultured immortalised HMCs, after long exposure to TGF-β1, exhibit a very similar phenotype to the described above for cancer-associated stromal cells. It is intriguing that only as much as 20% of these cultured cells express procollagen 11A1; this aspect warrants further analysis as well as the global genotype and phenotype of procollagen 11A1+ cells.

It has been reported that human bone marrow-derived mesenchymal cells may differentiate in vitro to fibroblast/myofibroblast-like cells under certain conditions, such as coculture with human colon carcinoma cells and TGF-β1, or prolonged exposure to conditioned medium from MDA-MB-231 breast cancer cells; these fibroblast/myofibroblast-like cells are able to promote tumour growth both in vitro and in vivo [36,44-47]. As the phenotype of procollagen 11A1+ "myofibroblasts" from colon adenocarcinoma resembles that of cultured TGF-β1-activated human bone marrow mesenchymal cells, all these observations add support to the tenet that at least some cancer-associated stromal cells, such as the procollagen 11A1+ ones, could be bone marrow-derived mesenchymal cells. Altogether, we may suggest that procollagen 11A1+ could be expressed by a more specialized subpopulation among "activated myofibroblasts".

Halsted et al. [14] reported the cytoplasmic, stromal and vascular immunostaining of both normal and malignant human breast tissues with polyclonal antisera to specific regions of N-terminal domains of human procollagen 11A1. Vargas et al. [30] immunodetected collagen 11A1 in the normal epithelium of human breast and Wu et al. [31] performed it in some human ovarian cancer cell lines, after applying another antibody preparation.

Table 3 Patient characteristics (N = 51)*

| Characteristic                        | Frequency | (%  ) |
|--------------------------------------|-----------|-------|
| Gender                               |           |       |
| Female                               | 19        | 37.3  |
| Male                                 | 32        | 62.7  |
| Age (years)                          |           |       |
| Median (range)                       | 70 (31-85)|       |
| Tumor size (cm)                      |           |       |
| Median (range)                       | 3.7 (0.5-11)|      |
| Localization                         |           |       |
| Ascending colon                      | 21        | 41.2  |
| Descending colon                     | 8         | 15.7  |
| Sigmoid                              | 22        | 43.1  |
| Differentiation                      |           |       |
| Well differentiated                  | 19        | 37.3  |
| Moderately differentiated            | 28        | 54.9  |
| Poorly differentiated                | 4         | 7.8   |
| T                                     |           |       |
| T1                                   | 3         | 5.9   |
| T2                                   | 7         | 13.7  |
| T3                                   | 28        | 54.9  |
| T4                                   | 13        | 25.5  |
| N                                     |           |       |
| pN0                                  | 25        | 49.0  |
| pN1                                  | 26        | 51.0  |
| M                                     |           |       |
| M0                                   | 39        | 76.5  |
| M1                                   | 12        | 23.5  |
| TNM staging                          |           |       |
| I                                     | 8         | 15.7  |
| II A                                 | 12        | 23.5  |
| II B                                 | 4         | 7.8   |
| IIIA                                 | 1         | 2.0   |
| IIIB                                 | 9         | 17.6  |
| IIIC                                 | 5         | 9.8   |
| IV                                    | 12        | 23.5  |
| Dukes staging                        |           |       |
| A                                     | 8         | 15.7  |
| B                                     | 16        | 31.4  |
| C                                     | 15        | 29.4  |
| D                                     | 12        | 23.5  |
| Anti-procollagen 11A1 immunostaining by score | | |
| 0                                    | 3         | 5.9   |
| 1                                    | 12        | 23.5  |
| 2                                    | 13        | 25.5  |
| 3                                    | 4         | 7.8   |
| 4                                    | 6         | 11.8  |
| 6                                    | 13        | 25.5  |
| Anti-procollagen 11A1 immunostaining |           |       |
| Low (≤2)                             | 28        | 54.9  |
| High (>2)                            | 23        | 45.1  |

(*) Patients diagnosed with colon adenocarcinoma. Patients diagnosed with ischemia were excluded.
Figure 3. Representative procollagen 11A1 immunostaining in colon adenocarcinoma. A) Score 1; B) Score 2; C) Score 4; D) Score 6. Arrowheads point to stained peritumoral stromal cells. E) Bowel ischemia; F) Non-malignant tissue. Scale bar 50 μm (400X). G) Dispersed granularity and H) Confluent granularity. Scale bar 20 μm (1000X).
Figure 4 Representative immunostaining of a colon adenocarcinoma: A) Procollagen 11A1 (immunoscore 6), B) Desmin, C) αSMA and D) Vimentin (these images were taken from the same area of serial sections; and of cultured stromal cells from the same case: E) Procollagen 11A1, F) Desmin, G) αSMA and H) Vimentin. Scale bar 50 μm (400x).
rather contradictory observations have been reported in relation to the kind of cells in which COL11A1 mRNA has been detected. While in situ hybridization studies have spotted its detection only in stromal cells [1,17], another study, based on differentially expressed gene analyses by GeneChip hybridization, has pointed to the over-expression of COL11A1 mRNA in tumour epithelia [13]; very recently, Cheon et al. [48] have reported, also through in situ hybridization and immunohistochemistry with the DMTX1/1E8.33 mAb of serous ovarian cancer, that "COL11A1 expression was confined to intra/peritumoral stromal cells and rare foci of tumor epithelial cells".

In our experience, the immunodetection of procollagen 11A1 with the DMTX1/1E8.33 mAb has never been observed in normal epithelial, vascular or stromal cells but in cancer-associated stromal cells; immunochemistry discrepancies between our observations and those above mentioned may be attributed to the different fine specificity of the applied antibody preparations. Besides this, transcription profiling studies of human colon biopsies obtained from active and inactive areas of ulcerative colitis and Crohn’s disease, compared with samples from infectious colitis and healthy controls, have shown that there are no differences in the expression levels of the COL11A1 gene between any of the above referred to conditions [49-53]. COL11A1/procollagen 11A1 expression is mostly absent in benign inflammatory processes such as breast sclerosing adenosis [16,54], chronic pancreatitis [41], and diverticulitis (our own observations; data not shown), and is rather low in familial adenomatosis polyposis adenomas [1,2]. Thus, the in vivo up-regulation

Table 4 Association between procollagen 11A1 expression and clinicopathological features

| Anti-procollagen 11A1 immunostaining (Median =2) | Low (≤2) | High (>2) | p |
|-----------------------------------------------|----------|-----------|---|
| Age (Median 70 years)                         |          |           |   |
| ≤ 70 years                                    | 13       | 14        | 0.304 |
| > 70 years                                    | 15       | 9         |   |
| Gender                                        |          |           |   |
| Female                                        | 18       | 14        | 0.802 |
| Male                                          | 10       | 9         |   |
| Localization                                  |          |           |   |
| Ascending colon                               | 9        | 12        | 0.260 |
| Descending colon                              | 6        | 2         |   |
| Sigmoid                                       | 13       | 9         | 0.200 |
| Tumor size (Median = 3.7 cm)                  |          |           |   |
| Small ≤3.7 cm                                 | 12       | 14        |   |
| Large >3.7 cm                                 | 16       | 9         | 0.370 |
| Differentiation                               |          |           |   |
| Well differentiated                            | 12       | 7         |   |
| Moderately differentiated                     | 15       | 13        |   |
| Poorly differentiated                          | 1        | 3         |   |
| T                                           |          |           |   |
| T1-T2                                        | 8        | 2         | 0.075 |
| T3-T4                                        | 20       | 21        |   |
| N                                           |          |           |   |
| Absent                                       | 17       | 8         |   |
| Present                                      | 11       | 15        | 0.059 |
| M                                           |          |           |   |
| Absent                                       | 25       | 14        |   |
| Present                                      | 3        | 9         | 0.017 |
| Stage grouping                                |          |           |   |
| I                                            | 7        | 1         | 0.141 |
| IIA                                          | 7        | 5         |   |
| IIB                                          | 2        | 2         |   |
| IIIA                                         | 1        | 0         |   |
| IIIB                                         | 6        | 3         |   |
| IIIC                                         | 2        | 3         |   |
| IV                                           | 3        | 9         |   |
| Dukes staging                                 |          |           |   |
| A                                            | 7        | 1         |   |
| B                                            | 9        | 7         |   |
| C                                            | 9        | 6         | 0.047 |
| D                                            | 3        | 9         |   |

Galván et al. BMC Cancer 2014, 14:867
http://www.biomedcentral.com/1471-2407/14/867
of the COL11A1 gene may be considered as a biomarker of cancer-associated stromal cells.

In this study, high procollagen 11A1 immunostaining was associated with clinicopathological variables such as lymph node involvement, advanced Dukes stages and presence of distant metastases. These results go according to the role of COL11A1 in promoting carcinoma aggressiveness and progression [11,17,20,30,31,48,55-57].

Conclusions
Based on its high specificity, our observations stress once more the usefulness of the DMTX1/1E8.33 mAb for cancer research, and the clinical significance of procollagen 11A1 as a very valuable biomarker to characterise cancer-associated stromal cells and to evaluate human colon adenocarcinomas.

Additional file

Additional file 1: Detailed description of patients and their clinico-pathological characteristics.

Abbreviations
HMCG: Human mesenchymal cells; hTERT-HMCG: Immortalised hTERT- human bone marrow mesenchymal cells; ICC: Immunocytochemistry; IHC: Immunohistochemistry; mAb: Monoclonal antibody; pAb: Polyclonal antibodies; H&E: Hematoxylin and eosin; PBS: Phosphate-buffered saline; DAB: 3′,3′-Diaminobenzidine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JAG carried out immunostainings, photographs and statistical analyses. The immunostainings were evaluated by JAG, CGP and C GR, and supervised by JAG and CGR. All authors discussed, read and approved the final manuscript. CGP, PMR, LBS, and JRT contributed equally to the study as senior authors.

Acknowledgements
The authors thank Ines Zlovec for the critical reading of the manuscript and helpful comments. The excellent technical assistance of Laura Suarez-Fernández is greatly acknowledged.

This research has been co-financed by European Union ERDF Funds; by the INNPACTO-ONCOPAN IPT-010000-2010-31 Project, by the FIS-09/PS09/01911 Project, Ministry of Science and Innovation, Spain; by the FC-11-PC10-23, FICYT Project, Axe 1 of the 2007–2013 ERDF Operational Framework Programme of the Principality of Asturias, Spain; and by Oncomatrix, S.L., Denio, Spain.

Author details
1. Surgery Department, School of Medicine and Health Sciences, University of Oviedo, 33006 Oviedo, Spain. 2. Oncology University Institute of the Principality of Asturias (IUOPA), 33006 Oviedo, Spain. 3. Preparative Biotechnology Unit, Technical-Scientific Services, University of Oviedo, 33006 Oviedo, Spain. 4. Pathological Anatomy Service, Asturias Central University Hospital (HUCA), 33006 Oviedo, Spain. 5. Immunology Department, School of Medicine and Health Sciences, University of Oviedo, c/ Julián Clavéita s/n, 33006 Oviedo, Spain. 6. Present address: Translational Research Unit (TRU), Institute of Pathology, University of Bern, Bern, Switzerland.

Received: 29 April 2014 Accepted: 12 November 2014

References
1. Fischer H, Stenling R, Rubio C, Lindblom A: Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis 2001, 22:875–878. doi:10.1039/carcin/22.6.875.
2. Fischer H, Salahshor S, Stenling R, Björk J, Lindmark G, Iselius L, Rubio C, Lindblom A: COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC Cancer 2001, 1:17 [http://www.biomedcentral.com/1471-2407/1/17].
3. Wang KK, Liu N, Radulovich N, Wöle DA, Johnston MR, Shepherd FA, Minden MD, Tsao MS: Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 2002, 21:7598–7604.
4. Xu SH, Qian LJ, Mou HZ, Zhu CH, Zhou XM, Liu XL, Chen Y, Yao WY: Difference of gene expression profiles between esophageal carcinoma and its precancerous epithelium by gene chip. World J Gastroenterol 2003, 9:417–422.
5. Sok JC, Kuriakose MA, Mahajan V, Pearlman AN, DeLacure MD, Chen FA: Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. Arch Otolaryngol Head Neck Surg 2003, 129:760–770.
6. Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, Wolf GT, Kuck R, Miske DE, Trask DK, Hanash S: Molecular profiling and the identification of genes associated with metastatic oral cavity/ pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130:295–302.
7. Croner RS, Fonteche VD, Guenther TM, Siebenhaar R, Matzel RE, Papadopoulos T, Kirchner T, Behrens J, Klein-Hitpass L, Stuerz M, Hohenberger W, Reingruber E: Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis 2005, 20:353–362.
8. Barneo L, del Arno I, García-Pravia C, de los Tores JR, Pérez-Basterrechea M, González-Pinto I, Vázquez L, Miya R, Simon L: Identification of specific genes by microarrays, validation and use of polyclonal antibodies in pancreatic cancer: preliminary results. In 41st Congress of the European Society for Surgical Research-ESSR 2006. Edited by Vollmar B. Bologna, Italy: Medimond, International Proceedings; 2006:27–35.
9. del Arno-Iribarren J: Identificación de marcadores para diagnóstico diferencial y potenciales dianas terapéuticas en adenocarcinoma ductal de páncreas mediante herramientas genómicas, PhD thesis. Universidad del País Vasco, Vascon, Physical Anthropology and Animal Physiology Department; 2006.
10. Chong W, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, Hung JY, Jou CH, Tsai MS, Hwang JJ, Lin SR: Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep 2006, 16:981–988.
11. Vecchi M, Niccurfo P, Romagnoli S, Confalonieri S, Pellegrini C, Sergo G, Quarto M, Capra M, Roviaro GC, Contessini Avesani E, Corsi C, Corbi G, Di Fiore PP, Bosari S: Gene expression of early and advanced gastric cancer. Oncogene 2007, 26:4284–4294.
12. Piarsky C, Ammerpohl P, Sipos B, Dahi E, Hartmann A, Wellmann A, Braunischweig T, Lühr M, Jesenofsky R, Fries H, Wente MN, Kristiansen G, Jahnke B, Dienz A, Rückert F, Schackert HK, Klöppel G, Kalthoff H, Saeger HD, Grützmacher R: Activation of Wnt signalling in stromal and pancreatic carcinoma identified by gene expression profiling. J Cell Mol Med 2008, 12:2823–2835.
13. Badea L, Herlea V, Dinu SA, Dumitrescu T, Popescu I: Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008, 55:1606–2027.
14. Halsted KC, Bowen KB, Bond L, Luman SE, Jorcyk CL, Fyffe WE, Kronz JD, Oxford JT: Colagen alpha1(X) in normal and malignant breast tissue. Mod Pathol 2008, 21:1245–1254.
15. Bowen KB, Reimers AP, Luman S, Kronz JD, Fyffe WE, Oxford JT: Immunohistochemical localization of collagen type XI alpha1 and alpha2 chains in human colon tissue. J Histochem Cytochem 2008, 56:275–283.
16. Fuentes-Martínez N: Colágeno I: Nuevo marcador en el cáncer de mama, PhD thesis. Universidad de Oviedo, Surgery and Medical Surgical Specialities Department; 2009.
17. Zhao Y, Zhou T, Li J, Yao H, He F, Wang L, Si J: A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Anat Rec 2009, 292:692–700.
18. An JH, Lee SY, Jeon JY, Cho KG, Kim SJ, Lee MA: Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 2009, 8:2873–2881.
19. Erkan M, Weis N, Pan Z, Schwarzer C, Samkhahzadeh T, Jiang X, Wirkner U, Giese NA, Ansorge W, Debuss J, Huber PE, Fries H, Abdollahi A, Klett J, Orhan, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer 2010, 9:88 [http://www.molecularcancer.com/content/9/1/88]

20. Kim H, Watkinson J, Varadan V, Anastassiou D. Multi-cancer computational analysis reveals invasion-associated variant of desmoplakin reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 2010, 3:51 [http://www.biomedcentral.com/1755-8794/3/51]

21. Pavilides S, Tirigos A, Vera I, Florenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martínez-Ontoso UE, Howell A, Sotgia F, Lisiati MP. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuronal-Glia Metabolic Coupling." Aging (Albany NY) 2010, 2:185–199.

22. Chernov AV, Baranovskaya S, Golubkov VS, Wakerman DR, Snyder EY, Williams R, Strongin AY. Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem 2010, 285:19647–19659.

23. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Mulik K, Miller CR, Randall SH, Sochinska MA, Parsons AM, Fankhouse KR, Lee CB, Roberts PJ, Thorne L, Bernard S, Perou CM, Hayes DN. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important and correspond to different normal cell types. Clin Cancer Res 2010, 16:4864–4875. doi:10.1158/1078-0432.CCR-10-1039.

24. Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan M, Vázquez F, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Giese NA, Ansorge W, Debu
54. Fuentes-Martínez N, García-Pravia C, García-Ocaña M, Menéndez-Rodríguez P, Del Amo J, Suárez-Fernández L, Galván JA, De Los Toyos JR, Barneo L: Overexpression of proCOL11A1 as a stromal marker of breast cancer. Histol Histopathol 2014, [Epub ahead of print].

55. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riss O, Wallwiener D, Kurek R, Neubauer HJ: Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006, 66:5278–5286.

56. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC: Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012, 72:4574–4586. doi:10.1158/0008-5472.CAN-12-0636.

57. Castellana B, Escuin D, Peiró G, García-Valdecasas B, Vázquez T, Pons C, Pérez-Olabarria M, Barnadas A, Lerma E: ASPN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas. J Cancer Educ 2012, 3:175–183. doi:10.7150/jca.4120.

doi:10.1186/1471-2407-14-867

Cite this article as: Galván et al.: Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. BMC Cancer 2014 14:867.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit